Indeed, preclinical anti-tumour activity of PARP inhibitors has been observed in combination with chemotherapy and beta particle emitting targeted radiotherapy agents29,30 and more recently, PARP inhibitors have been shown to enhance the formation and persistence of cytotoxic double strand DNA breaks and potentiate the cytotoxicity of LuTate in vitro31,32. This evidence concerns the gene PARP1 and neoplasm.